REFERENCES
1. Serrano PE, Parpia S, Linkins LA, et al. Venous thromboembolic events following major pelvic and abdominal surgeries for cancer: a prospective cohort study. Ann Surg Oncol 2018;25:3214-21.
2. Abdulla A, Davis WM, Ratnaweera N, Szefer E, Ballantyne Scott B, Lee AYY. A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 2020;120:702-13.
3. Moik F, Chan WE, Wiedemann S, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 2021;137:1669-78.
4. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-64.
5. Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers 2022;8:11.
6. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020;38:496-520.
7. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 2013;11:223-33.
8. Dickmann B, Ahlbrecht J, Ay C, et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 2013;98:1309-14.
9. Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004;2:1760-5.
10. Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 2009;22:49-60.
11. Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017;117:219-30.
12. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:2377-81.
13. Ramsey G, Lindholm PF. Thrombosis risk in cancer patients receiving red blood cell transfusions. Semin Thromb Hemost 2019;45:648-56.
14. Branchford BR, Carpenter SL. The role of inflammation in venous thromboembolism. Front Pediatr 2018;6:142.
15. Willobee BA, Dosch AR, Allen CJ, et al. Minimally invasive surgery is associated with an increased risk of postoperative venous thromboembolism after distal pancreatectomy. Ann Surg Oncol 2020;27:2498-505.
16. Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021;5:301-25.
17. Lisman T, Caldwell SH, Intagliata NM. Haemostatic alterations and management of haemostasis in patients with cirrhosis. J Hepatol 2022;76:1291-305.
18. Zanetto A, Campello E, Pelizzaro F, et al. Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. Liver Int 2022;42:1229-40.
19. Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer: a population-based cohort study. Thromb Haemost 2017;117:57-65.
20. Zanetto A, Senzolo M, Vitale A, et al. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis 2017;49:440-5.
21. Kinoshita A, Onoda H, Imai N, et al. Elevated plasma fibrinogen levels are associated with a poor prognosis in patients with hepatocellular carcinoma. Oncology 2013;85:269-77.
22. Thorson CM, Van Haren RM, Ryan ML, et al. Pre-existing hypercoagulability in patients undergoing potentially curative cancer resection. Surgery 2014;155:134-44.
23. Simpson-haidaris P, Rybarczyk B. Tumors and fibrinogen: the role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci 2001;936:406-25.
24. Zanetto A, Campello E, Bulato C, et al. More pronounced hypercoagulable state and hypofibrinolysis in patients with cirrhosis with versus without HCC. Hepatol Commun 2021;5:1987-2000.
25. Campello E, Zanetto A, Spiezia L, et al. Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. Thromb Res 2016;143:118-21.
26. Carr BI, Guerra V, Giannini EG, et al. Italian Liver Cancer Group. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. Int J Biol Markers 2014;29:e215-23.
27. Wang B, Zhu J, Ma X, et al. Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma. Clin Chim Acta 2019;495:191-7.
28. Liu PH, Hsu CY, Su CW, et al. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver Int 2020;40:2522-34.
30. Scheiner B, Kirstein M, Popp S, et al. Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma. Liver Cancer 2019;8:203-17.
31. Hagiwara S, Kudo M, Kawasaki T, et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol 2006;41:1214-9.
32. Gade IL, Braekkan SK, Naess IA, et al. The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. J Thromb Haemost 2017;15:1567-75.
33. Hwang SJ, Luo JC, Li CP, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 2004;10:2472-7.
34. Zanetto A, Senzolo M, Campello E, et al. Influence of hepatocellular carcinoma on platelet aggregation in cirrhosis. Cancers 2021;13:1150.
35. Trebicka J, Fernandez J, Papp M, et al. PREDICT STUDY group of the EASL-CLIF Consortium. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol 2020;73:842-54.
36. Lesmana CR, Inggriani S, Cahyadinata L, Lesmana LA. Deep vein thrombosis in patients with advanced liver cirrhosis: a rare condition? Hepatol Int 2010;4:433-8.
37. Yassine A, Abureesh M, Hamadi R, Dahabra L, Alshami M, Liliane D. Predictors of deep venous thrombosis in hospitalized patients with liver cirrhosis in the US. Cureus 2022;14:e23450.
38. Faccia M, Santopaolo F, Gasbarrini A, Pompili M, Zocco MA, Ponziani FR. Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients. Intern Emerg Med 2022;17:1327-34.
39. Connolly GC, Chen R, Hyrien O, et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res 2008;122:299-306.
40. Wang Y, Attar BM, Fuentes HE, Yu J, Zhang H, Tafur AJ. Performance of Khorana risk score for prediction of venous thromboembolism in patients with hepatocellular carcinoma. Clin Appl Thromb Hemost 2018;24:471-6.
41. Al-Taee AM, Mohammed KA, Khneizer GW, Neuschwander-Tetri BA. Correlates, trends, and short-term outcomes of venous thromboembolism in hospitalized patients with hepatocellular carcinoma. J Gastrointest Cancer 2019;50:357-60.
42. Chen Y, Zhao J, Zhang Z, et al. Construction and validation of a nomogram for predicting the risk of deep vein thrombosis in hepatocellular carcinoma patients after laparoscopic hepatectomy: a retrospective study. J Hepatocell Carcinoma 2021;8:783-94.
43. Association for the Study of the Liver. Electronic address: [email protected]. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol 2016;64:179-202.
44. Senzolo M, Shalaby S, Grasso M, et al. Role of nonneoplastic PVT in the natural history of patients with cirrhosis and first diagnosis of HCC. Hepatology 2024;79:355-67.
45. Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl 2019;25:207-16.
46. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999;29:62-7.
47. Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2001;233:379-84.
48. Nonami T, Yokoyama I, Iwatsuki S, Starzl TE. The incidence of portal vein thrombosis at liver transplantation. Hepatology 1992;16:1195-8.
49. Davidson BR, Gibson M, Dick R, Burroughs A, Rolles K. Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation. Transplantation 1994;57:1174-7.
50. Ravaioli M, Zanello M, Grazi GL, et al. Portal vein thrombosis and liver transplantation: evolution during 10 years of experience at the University of Bologna. Ann Surg 2011;253:378-84.
51. Cagin YF, Atayan Y, Erdogan MA, Dagtekin F, Colak C. Incidence and clinical presentation of portal vein thrombosis in cirrhotic patients. Hepatobiliary Pancreat Dis Int 2016;15:499-503.
52. Serag WM, Mohammed BSE, Mohamed MM, Elsayed BE. Predicting the risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. Heliyon 2020;6:e04677.
53. O'Shea RS, Davitkov P, Ko CW, et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis. Gastroenterology 2021;161:1615-1627.e1.
54. Association for the Study of the Liver. Electronic address: [email protected], European Association for the Study of the Liver. EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 2022;76:1151-84.
55. Valeriani E, Di Nisio M, Riva N, et al. Anticoagulant treatment for splanchnic vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Thromb Haemost 2021;121:867-76.
56. Candeloro M, Valeriani E, Monreal M, et al. Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Blood Adv 2022;6:4516-23.
57. Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension. J Hepatol 2022;76:959-74.
